Captrust Financial Advisors Sells 12,219 Shares of Harrow, Inc. (NASDAQ:HROW)

Captrust Financial Advisors trimmed its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 14.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,920 shares of the company's stock after selling 12,219 shares during the quarter. Captrust Financial Advisors owned about 0.20% of Harrow worth $2,446,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of HROW. Barclays PLC lifted its stake in shares of Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after buying an additional 39,506 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Brookstone Capital Management acquired a new position in Harrow during the 4th quarter valued at $275,000. SG Americas Securities LLC raised its stake in Harrow by 158.5% during the 4th quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after purchasing an additional 18,815 shares during the last quarter. Finally, Sonora Investment Management Group LLC acquired a new position in Harrow during the 4th quarter valued at $518,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Price Performance

Shares of HROW stock traded down $1.14 during mid-day trading on Wednesday, reaching $25.13. The company's stock had a trading volume of 512,290 shares, compared to its average volume of 500,321. Harrow, Inc. has a 1-year low of $15.78 and a 1-year high of $59.23. The company has a market cap of $921.89 million, a P/E ratio of -26.73 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm's 50-day moving average is $24.85 and its two-hundred day moving average is $32.27.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. On average, research analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

Analyst Ratings Changes

HROW has been the subject of several research analyst reports. B. Riley cut their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright upped their target price on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.